Nan Shan Life Insurance’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $17.7M | Buy |
138,611
+78,347
| +130% | +$9.78M | 0.64% | 49 |
|
|
2025
Q4 | $7.35M | Hold |
60,264
| – | – | 0.23% | 65 |
|
|
2025
Q3 | $6.04M | Sell |
60,264
-1,200
| -2% | -$108K | 0.13% | 90 |
|
|
2025
Q2 | $5.1M | Sell |
61,464
-3,400
| -5% | -$271K | 0.11% | 96 |
|
|
2025
Q1 | $5.26M | Hold |
64,864
| – | – | 0.12% | 93 |
|
|
2024
Q4 | $5.84M | Hold |
64,864
| – | – | 0.14% | 88 |
|
|
2024
Q3 | $6.41M | Hold |
64,864
| – | – | 0.15% | 76 |
|
|
2024
Q2 | $6.01M | Sell |
64,864
-160
| -0.2% | -$14.3K | 0.14% | 86 |
|
|
2024
Q1 | $6.17M | Sell |
65,024
-3,880
| -6% | -$360K | 0.15% | 86 |
|
|
2023
Q4 | $6.15M | Sell |
68,904
-6,850
| -9% | -$509K | 0.15% | 81 |
|
|
2023
Q3 | $5.53M | Sell |
75,754
-2,400
| -3% | -$192K | 0.15% | 79 |
|
|
2023
Q2 | $6.5M | Sell |
78,154
-4,400
| -5% | -$368K | 0.16% | 84 |
|
|
2023
Q1 | $6.29M | Sell |
82,554
-3,738
| -4% | -$310K | 0.15% | 84 |
|
|
2022
Q4 | $7.16M | Sell |
86,292
-2,700
| -3% | -$219K | 0.2% | 75 |
|
|
2022
Q3 | $7.06M | Buy |
88,992
+2,600
| +3% | +$219K | 0.17% | 81 |
|
|
2022
Q2 | $6.42M | Buy |
86,392
+2,238
| +3% | +$168K | 0.13% | 85 |
|
|
2022
Q1 | $7.56M | Sell |
84,154
-868
| -1% | -$80.2K | 0.13% | 81 |
|
|
2021
Q4 | $9.52M | Hold |
85,022
| – | – | 0.14% | 86 |
|
|
2021
Q3 | $10.7M | Hold |
85,022
| – | – | 0.18% | 86 |
|
|
2021
Q2 | $11.5M | Buy |
85,022
+33,200
| +64% | +$4.36M | 0.19% | 89 |
|
|
2021
Q1 | $7.03M | Buy |
51,822
+9,822
| +23% | +$1.47M | 0.14% | 104 |
|
|
2020
Q4 | $5.91M | Sell |
42,000
-12,226
| -23% | -$1.57M | 0.12% | 108 |
|
|
2020
Q3 | $6.04M | Buy |
+54,226
| New | +$6.08M | 0.16% | 90 |
|
|
2020
Q2 | – | Sell |
-12,300
| Closed | -$953K | – | 116 |
|
|
2020
Q1 | $953K | Hold |
12,300
| – | – | 0.03% | 91 |
|
|
2019
Q4 | $1.17M | Sell |
12,300
-3,051
| -20% | -$264K | 0.04% | 86 |
|
|
2019
Q3 | $1.17M | Hold |
15,351
| – | – | 0.03% | 83 |
|
|
2019
Q2 | $1.35M | Hold |
15,351
| – | – | 0.03% | 88 |
|
|
2019
Q1 | $1.39M | Hold |
15,351
| – | – | 0.03% | 99 |
|
|
2018
Q4 | $1.1M | Sell |
15,351
-4,900
| -24% | -$395K | 0.03% | 103 |
|
|
2018
Q3 | $1.94M | Sell |
20,251
-10,049
| -33% | -$974K | 0.04% | 99 |
|
|
2018
Q2 | $2.88M | Sell |
30,300
-39,900
| -57% | -$3.67M | 0.07% | 89 |
|
|
2018
Q1 | $6.16M | Buy |
+70,200
| New | +$6.41M | 0.13% | 83 |
|
Other funds holding XBI
Nan Shan Life Insurance's XBI Position: Q1 2026 in Review
Nan Shan Life Insurance increased its State Street SPDR S&P Biotech ETF (XBI) stake by 130% in Q1 2026, buying an estimated $9.78M and bringing the position to 138,611 shares worth $17.7M. The position accounts for 0.64% of the portfolio, ranked #49.
Nan Shan Life Insurance first reported a position in XBI in Q1 2018 and has held it in 32 quarters since. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Nan Shan Life Insurance held 138,611 shares of State Street SPDR S&P Biotech ETF worth $17.7M as of Q1 2026.
- Nan Shan Life Insurance bought 78,347 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $9.78M.
- State Street SPDR S&P Biotech ETF made up 0.64% of Nan Shan Life Insurance's portfolio in Q1 2026, its #49 holding.
- Nan Shan Life Insurance first reported a position in State Street SPDR S&P Biotech ETF in Q1 2018 and has held it in 32 quarters since.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Nan Shan Life Insurance's 13F filing for Q1 2026, filed 14 May 2026.